Inovio wins prestigious Edward Jenner Poster Award for cervical cancer vaccine research
Inovio Pharmaceuticals (AMEX:INO) won the Edward Jenner Poster Award First Prize for its research to develop a therapeutic, synthetic vaccine for cancer.
Articles by proactiveinvestors
NanoViricides Reports Positive Anti-viral Effect of HIV Drug
NanoViricides’ anti-HIV drug candidate, HIVCide, achieved a positive, long-term effect with fewer and weaker doses than the traditional anti-retroviral combination therapy.
Bacterin Receives $15 Million Credit Facility
Bacterin International Holdings (AMEX:BONE) announced Tuesday it secured a 42 month-long, $15 million credit facility with MidCap Financial LLC and Silicon Valley Bank.
IntelliCell BioSciences To Open Adipose Tissue Processing Center in Houston
IntelliCell BioSciences, Inc. (OTCQB: SVFC), maker of stromal vascular fraction that contains adipose derived adult stem cells opens new processing center in Houston, Texas.
Bio-Rad receives pre-market approval for HIV test from FDA
Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test.
Drug maker GlaxoSmithKline receives upbeat results in Promacta phase three study
Biotech company Ligand Pharmaceuticals Inc. reported Tuesday that its partner GlaxoSmithKline received encouraging results in Hepatitis C study.
E-Therapeutics expects to generate a “wealth of data” from clinical trials
E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.
Novartis’ NVA237 improves lung function in pulmonary disease patients
Swiss drug maker Novartis said results from a phase three study remarkably improved lung function in a similar way to a rival drug.
Inherent value to be “developed and extracted” at Amphion
Amphion Innovations (LON:AMP) said it believes there is “significant inherent value to be developed and extracted” from its partner companies, when it released its annual […]
Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
NeoStem announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line.